(MRK) Merck KGaA - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: DE0006599905
MRK: Chemicals, Equipment, Drugs, Biopharmaceuticals, Semiconductors
Merck KGaA, a Germany-based science and technology company founded in 1668, operates through three core segments: Life Science, Healthcare, and Electronics. The Life Science division provides tools, chemicals, and equipment for academic laboratories, biotech firms, pharmaceutical manufacturers, and industrial clients. It specializes in continuous bioprocessing technologies, testing kits, reagents, and solutions for analyzing air, water, and soil quality. Additionally, it offers tools for testing nutritional values and identifying quality inconsistencies in products.
The Healthcare segment focuses on the discovery, development, manufacturing, and marketing of prescription drugs and biopharmaceuticals. Its portfolio includes treatments for oncology, neurology, immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. The segment also offers general medicines, injection devices, and disease monitoring software. Recent in-licensing agreements with Debiopharm International SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., and Abbisko Therapeutics Co. Ltd. expand its pipeline in oncology and rare diseases.
The Electronics segment supplies advanced materials for the semiconductor and display industries, including delivery systems, surface solutions, and functional materials. It also provides cosmetic effect pigments and functional solutions for industrial applications. Merck KGaA, headquartered in Darmstadt, Germany, operates as a subsidiary of E. Merck KG and is listed on the XETRA under the ticker symbol MRK. For more information, visit https://www.merckgroup.com/en.
Based on
Additional Sources for MRK Stock
MRK Stock Overview
| Market Cap in USD | 57,635m |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception |
MRK Stock Ratings
| Growth Rating | -3.98 |
| Fundamental | 24.9 |
| Dividend Rating | 40.8 |
| Rel. Strength | -18.1 |
| Analysts | - |
| Fair Price Momentum | 111.39 EUR |
| Fair Price DCF | 352.02 EUR |
MRK Dividends
| Dividend Yield 12m | 1.63% |
| Yield on Cost 5y | 2.35% |
| Annual Growth 5y | -3.29% |
| Payout Consistency | 90.0% |
MRK Growth Ratios
| Growth Correlation 3m | -89.9% |
| Growth Correlation 12m | -85.3% |
| Growth Correlation 5y | 14.5% |
| CAGR 5y | 5.31% |
| CAGR/Max DD 5y | 0.11 |
| Sharpe Ratio 12m | -0.55 |
| Alpha | -26.10 |
| Beta | 0.470 |
| Volatility | 27.84% |
| Current Volume | 410.2k |
| Average Volume 20d | 386.5k |
As of May 01, 2025, the stock is trading at EUR 121.90 with a total of 410,162 shares traded.
Over the past week, the price has changed by +2.95%, over one month by -1.93%, over three months by -15.19% and over the past year by -16.65%.
Neither. Based on ValueRay Fundamental Analyses, Merck KGaA is currently (May 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 24.86 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MRK as of May 2025 is 111.39. This means that MRK is currently overvalued and has a potential downside of -8.62%.
Merck KGaA has no consensus analysts rating.
According to ValueRays Forecast Model, MRK Merck KGaA will be worth about 121.3 in May 2026. The stock is currently trading at 121.90. This means that the stock has a potential downside of -0.48%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 172.3 | 41.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 121.3 | -0.5% |